We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Alternative Therapy for Ear Infections

By HospiMedica staff writers
Posted on 05 Sep 2000
A panel of pediatricians and otolaryngologists from the American Academy of Pediatrics has determined that a topical antibiotic is an acceptable alternative to oral antibiotics for treating children with ear tubes who develop ear infections. The findings of the panel, which met in Boston (MA, USA), are to be published in a future issue of the Pediatric Infectious Disease Journal.

The traditional treatment for children with middle ear infections is oral antibiotics. However, the incidence of antibiotic resistance is increasing. As the use of oral antibiotics grows, so does the incidence of resistance. Doctors place ear tubes in many children who have recurring infections to deter infection, but some children still become infected. Middle ear infections and drainage in these children can be treated with Floxin (ofloxacin otic solution, 0.3%), atopical antibiotic, said the panel.

"A topical antibiotic can be the first-line treatment of choice when treating ear drainage and infected ear tubes, if there is no underlying systemic infection,” stated panelist Seth Pransky, M.D., director, pediatric otolaryngology at Children's Hospital, San Diego, CA, USA.

Floxin has been cleared by the U.S. Food and Drug Administration (FDA) for otitis externa in patients aged one year or older (due to Pseudomonas aeruginosa and Staphylococcus aureus), acute otitis media in pediatric patients aged one year or older with tympanostomy tubes (due to P aeruginosa, S aureus, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae), and chronic suppurative otitis media in patients 12 years or older with perforated tympanic membranes (due to P aeruginosa, S aureus, or Proteus mirabilis). Floxin is the product of Daiichi Pharmaceutical Corp. (Tokyo, Japan).

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Adjustable Shower Trolley
ST 370
New
Mattress
Powered Therapeutic Mattress

Latest Patient Care News

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization